Cash Flow from Financial Activities: The net amount of cash transactions used in funding activities.
C4 Therapeutics, Inc. (CCCC) had Cash Flow from Financial Activities of $45.49M for the most recently reported fiscal year, ending 2023-12-31.
| Income Statement Financials | |
$20.76M |
|
$-132.49M |
|
-- |
|
$20.76M |
|
$159.79M |
|
$-139.03M |
|
$7.82M |
|
$-131.21M |
|
$-131.21M |
|
$-132.49M |
|
$-132.49M |
|
$-132.49M |
|
$-132.49M |
|
$-139.03M |
|
$-140.53M |
|
49.64M |
|
49.64M |
|
$-2.67 |
|
$-2.67 |
|
| Balance Sheet Financials | |
$271.19M |
|
$7.13M |
|
$105.26M |
|
$376.45M |
|
$42.77M |
|
-- |
|
$87.57M |
|
$130.34M |
|
$246.11M |
|
$246.11M |
|
$246.11M |
|
60.47M |
|
| Cash Flow Statement Financials | |
$-106.84M |
|
$158.35M |
|
|
Cash Flow from Financial Activities |
$45.49M |
$33.03M |
|
$130.03M |
|
$97.00M |
|
$27.23M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.34 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-669.84% |
|
-669.84% |
|
-677.06% |
|
-632.17% |
|
-638.34% |
|
$-108.55M |
|
-- |
|
-- |
|
-- |
|
0.06 |
|
-- |
|
1.76 |
|
207.49 |
|
-53.83% |
|
-53.83% |
|
-35.20% |
|
-53.83% |
|
$4.07 |
|
$-2.19 |
|
$-2.15 |
|